Apr 16 |
Foghorn Therapeutics appoints Kristian Humer as chief financial officer
|
Apr 16 |
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
|
Apr 9 |
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
|
Apr 9 |
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
|
Apr 5 |
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
|
Apr 2 |
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
|
Mar 26 |
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
|
Mar 13 |
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
|
Mar 13 |
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
|
Mar 7 |
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
|